ShareValue scores for OBI.LSE: Valuation 32, Quality 27, Growth 46, Health 51.

OBI.LSE
LSE

Ondine Biomedical Inc

£0.13(0.00%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-7% to 11%
Valuation
32
Overvalued
Price vs Value
Quality
27
Weak
Business Strength
Growth
46
Moderate
Revenue & Earnings
Health
51
Moderate
Financial Stability
Momentum
73
Bullish
Price Trend

Company Details

About

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as catheter-associated urinary tract infection. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026